Total Revenue of $1.4 billion in 4Q25 and $5.4 billion in FY25 Adjusted EBITDAR Margin of 35% in 4Q25 and 31% in FY25, highest on record Operating Margin of 21% in 4Q25 and 17% in FY25 Premium revenue at 42% in 4Q25 and FY25MEXICO CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) — Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO, “Aeroméxico” or the “Company”) today reported unaudited consolidated financial results for the three months ended December 31, 2025 (“4Q25”) and twelve months ended December 31, 2025 (“FY25”) and as of December 31, 2025. The unaudited consolidated financial results set forth below are subject to revision based upon the completion of our annual financial closing process, and other developments arising between now and the time this financial closing process is finalized. These results are based on information...

Company Hosting New York Investor Day Meeting February 17th HARTSVILLE, S.C., Feb. 16, 2026 (GLOBE NEWSWIRE) — Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), a global leader in high-value sustainable packaging, today reported financial results for the fourth quarter and full year ended December 31, 2025. Summary:Grew fourth quarter net sales to $1.8 billion, up 29.7% from the prior-year quarter, primarily from acquisition activity Reported fourth quarter U.S. generally accepted accounting principles (“GAAP”) net income attributable to Sonoco of $332.2 million, up from a loss of $(43.0) million in the same period in 2024, GAAP operating profit of $520.2 million, up from $56.1 million in the same period in 2024, and diluted earnings/(loss) per share (“EPS”) attributable to Sonoco of $3.33, up from $(0.44) in the...

Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2025. A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will...

GAAP Net Loss of $0.01 Per Diluted Share for the Fourth Quarterand $0.08 per Diluted Share for the Full Year Normalized FFO of $0.29 Per Diluted Share for the Fourth Quarter and $1.08 per Diluted Share for the Full Year Office Same Store NOI Growth of 10.4% (GAAP)Positive Office Renewal Spreads of 9.1% (GAAP) and 2.5% (Cash) Positive Retail Renewal Spreads of 15.3% (GAAP) and 10.1% (Cash) VIRGINIA BEACH, Va., Feb. 16, 2026 (GLOBE NEWSWIRE) — Armada Hoffler Properties, Inc. (NYSE: AHH) today announced its results for the quarter ended December 31, 2025 and provided an update on current events and earnings guidance. Fourth Quarter and Recent Highlights:Net loss attributable to common stockholders and OP Unitholders of $1.0 million, or $0.01 per diluted share, compared to net income attributable to common stockholders and OP Unitholders...

Aspo Plc Financial Statements Release February 16, 2026, at 9.00 EET Aspo Plc’s Financial Statements Release, January 1 – December 31, 2025: A year with significant profit improvement in a challenging market This is a summary of the Financial Statements Release January 1 – December 31, 2025 of Aspo Plc. The complete report is attached to this release and available at aspo.com. October–December 2025Net sales, Group total was EUR 158.0 (159.8) million Net sales from continuing operations decreased to EUR 119.3 (124.5) million Comparable EBITA, Group total grew to EUR 8.9 (8.0) million, 5.7% (5.0%) of net salesESL Shipping EUR 3.8 (4.3) million Telko EUR 4.4 (3.9) million Discontinued operation EUR 2.0 (1.1) million Other operations EUR -1.2 (-1.2) millionEBITA, Group total was EUR 16.2 (8.1) million. EBITA of ESL Shipping was EUR...

BEIJING, Feb. 15, 2026 (GLOBE NEWSWIRE) — Leishen Energy Holding Co., Ltd. (“Leishen Energy,” the “Company”) (Nasdaq: LSE) announced its fiscal year 2025 financial results on January 30, 2026, reflecting a transition period: core operating performance weakened, but the Company strengthened its financial foundation through the IPO, reduced leverage, and improved liquidity. The Company’s cash position and low debt levels provide flexibility to address operational challenges, while continued improvements in asset quality help mitigate financial risks. Fiscal Year 2025 Financial Highlights Total revenues declined from USD $63.5 million to USD $48.3 million due to the economic downturn, particularly the overall sluggishness in the oil and gas market, coupled with customers’ cost pressures, weaker market demand, and the impact of the...

WALNUT, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) — Armlogi Holding Corp. (“Armlogi” or the “Company”) (Nasdaq: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, today announced financial results for its fiscal 2026 second quarter and six-month period ended December 31, 2025. Financial Results for the Three Months Ending December 31, 2025:Total revenue increased 0.8% to $51.5 million for the three months ended December 31, 2025, compared to $51.1 million in the prior-year period.Costs of services increased to $52.3 million for the three months ended December 31, 2025, resulting in a gross loss of $0.8 million, compared to a gross profit of $0.5 million in the prior year period. Gross margin declined...

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce its unaudited results as at and for the three and six months ended December 31, 2025. As at December 31, 2025, the Company had cash, investments and digital assets of $23.4 million. As at December 31, 2025, net asset value per share was $0.27 as compared to $0.40 as at June 30, 2025. (See “Use of Non-GAAP Financial Measures” elsewhere) Financial Highlights for the three and six months ending December 31, 2025 with comparatives:Operating Results Three months ended December 31, Six months ended December 31,    2025     2024     2025     2024  Net...

CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.6 million, or $0.42 per diluted share, on net sales of $34.8 million for the second quarter of fiscal year 2026 compared to a net loss of $2.2 million, or $0.37 per diluted share, in the second quarter of the prior fiscal year. Net sales during the three months ended December 31, 2025, increased $0.7 million, or 2%, to $34.8 million as compared to $34.1 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 2% to $32.8 million. Private-label contract manufacturing sales increased primarily due to increased orders...

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2025 and provided an update on its business. During the first quarter, Edesa progressed manufacturing of its dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), and placebo for an upcoming Phase 2 study in moderate-to-severe nonsegmental vitiligo. The company anticipates recruitment will begin midyear 2026, subject to regulatory approvals. In its respiratory program, Edesa reported that it is evaluating subgroup data for additional efficacy signals among subjects with certain comorbidities following positive results from a Phase 3 study of...